NGNE
Neurogene Inc.
$31.53
+$0.74(+2.40%)
55
Overall
--
Value
90
Tech
21
Quality
Market Cap
$463.79M
Volume
308.96K
52W Range
$14.65 - $37.27
Target Price
$78.75
Company Overview
| Mkt Cap | $463.79M | Price | $31.53 |
| Volume | 308.96K | Change | +2.40% |
| P/E Ratio | -5.1 | Open | $31.52 |
| Revenue | -- | Prev Close | $30.79 |
| Net Income | $-90.4M | 52W Range | $14.65 - $37.27 |
| Div Yield | N/A | Target | $78.75 |
| Overall | 55 | Value | -- |
| Quality | 21 | Technical | 90 |
No chart data available
About Neurogene Inc.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company is headquartered in New York, New York.
Latest News
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Lyell Immunopharma (LYEL)
Christine Brown•11 days ago
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Lyell Immunopharma (LYEL)
Christine Brown•11 days ago
Analysts Offer Insights on Healthcare Companies: Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and Milestone Pharmaceuticals (MIST)
Brian Anderson•24 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NGNE | $31.53 | +2.4% | 308.96K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |